ALNYLAM PHARMACEUTICALS, INC.ALNYEarnings & Financial Report
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
ALNY Q1 FY2026 Key Financial Metrics
Revenue
$1.2B
Gross Profit
$959.7M
Operating Profit
$268.6M
Net Profit
$206.0M
Gross Margin
82.2%
Operating Margin
23.0%
Net Margin
17.6%
YoY Growth
96.4%
EPS
$1.51
ALNYLAM PHARMACEUTICALS, INC. Q1 FY2026 Financial Summary
ALNYLAM PHARMACEUTICALS, INC. reported revenue of $1.2B (up 96.4% YoY) for Q1 FY2026, with a net profit of $206.0M (17.6% margin). Cost of goods sold was $207.5M, operating expenses totaled $691.0M.
Key Financial Metrics
| Total Revenue | $1.2B |
|---|---|
| Net Profit | $206.0M |
| Gross Margin | 82.2% |
| Operating Margin | 23.0% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
ALNYLAM PHARMACEUTICALS, INC. Q1 FY2026 revenue of $1.2B breaks down across 7 segments, led by AMVUTTRA at $889.9M (76.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| AMVUTTRA | $889.9M | 76.2% |
| GIVLAARI | $74.4M | 6.4% |
| OXLUMO | $51.3M | 4.4% |
| Royalty revenue | $49.0M | 4.2% |
| Regeneron Pharmaceuticals | $46.3M | 4.0% |
| Roche | $35.6M | 3.1% |
| ONPATTRO | $20.5M | 1.8% |
ALNYLAM PHARMACEUTICALS, INC. Revenue by Segment — Quarterly Trend
ALNYLAM PHARMACEUTICALS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as AMVUTTRA and GIVLAARI) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| AMVUTTRA | $889.9M | — | — | — |
| GIVLAARI | $74.4M | $56.3M | $50.4M | $55.2M |
| OXLUMO | $51.3M | — | $20.7M | $16.0M |
| Royalty revenue | $49.0M | — | — | — |
| Regeneron Pharmaceuticals | $46.3M | — | — | — |
ALNYLAM PHARMACEUTICALS, INC. Annual Revenue by Year
ALNYLAM PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.7B).
ALNYLAM PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
ALNYLAM PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.2B | +96.4% | $206.0M | 17.6% |
| Q4 FY2025 | $1.1B | +84.9% | $186.4M | 17.0% |
| Q3 FY2025 | $1.2B | +149.3% | $251.1M | 20.1% |
| Q2 FY2025 | $773.7M | +17.3% | $-66.3M | -8.6% |
| Q1 FY2025 | $594.2M | +20.2% | $-57.5M | -9.7% |
| Q4 FY2024 | $593.2M | +34.9% | $-83.8M | -14.1% |
| Q3 FY2024 | $500.9M | -33.3% | $-111.6M | -22.3% |
| Q2 FY2024 | $659.8M | +107.0% | $-16.9M | -2.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $659.8M | $500.9M | $593.2M | $594.2M | $773.7M | $1.25B | $1.10B | $1.17B |
| YoY Growth | 107.0% | -33.3% | 34.9% | 20.2% | 17.3% | 149.3% | 84.9% | 96.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $4.01B | $4.21B | $4.24B | $4.21B | $4.57B | $4.85B | $4.97B | $5.13B |
| Liabilities | $4.01B | $4.17B | $4.17B | $4.10B | $4.32B | $4.62B | $4.18B | $4.05B |
| Equity | $-3.1M | $32.4M | $67.1M | $115.4M | $250.6M | $233.9M | $789.2M | $1.08B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $124.2M | $43.7M | $-94.7M | $-118.3M | $153.7M | $325.1M | $163.6M |